Our Terms of Service and Privacy Policy have changed.

By continuing to use this site, you are agreeing to the new Privacy Policy and Terms of Service.

First Trust NYSE Arca Biotechnology Index Fund (FBT)

Delayed Data
As of 3:59pm ET
 +1.22 / +1.09%
Today’s Change
Today|||52-Week Range

Investment Objective

The investment seeks investment results that correspond generally to the price and yield (before the fund's fees and expenses) of an equity index called the NYSE Arca Biotechnology Index(SM). The fund will normally invest at least 90% of its net assets (including investment borrowings) in common stocks that comprise the index. The index is an equal-dollar weighted index designed to measure the performance of a cross section of companies in the biotechnology industry that are primarily involved in the use of biological processes to develop products or provide services. It is non-diversified.


1 month+10.14% 3 years+35.00%
3 months+5.99% 5 years+25.97%
1 year+11.32% Since inception+20.22%
Data through 11/25/2015

Quote Details

Previous close$112.20
Open day’s range112.13 – 113.71
Net asset value (NAV)112.11 (11/24/2015)
Daily volume96,288
Average volume (3 months)235,780
Data as of 3:59pm ET, 11/25/2015

Peer Comparisonvs. Health ETFs

Performance 5-yr return+25.97%+20.45%
Expense Gross exp ratio0.58%0.47%
Risk 5 year sharpe ratio1.061.34
Net assets$3.1B$1.7B
Average market cap$9.2B$35.0B
Average P/E29.624.4
Dividend / Share--0.21%


XLV Health Care Select Sector SPDR® Fund
VHT Vanguard Health Care Index Fund ETF Shar...
RYH Guggenheim S&P 500® Equal Weight Health...


Top 5 Sectors
Portfolio weighting
Healthcare 100.00%
Business service 0.00%
Consumer goods 0.00%
Consumer service 0.00%
Energy 0.00%
Top 10 Holdings
Portfolio weighting
ALKS Alkermes Plc3.74%
UTHR United Therapeutics Corp3.61%
VRTX Vertex Pharmaceuticals Inc3.57%
ISIS Isis Pharmaceuticals Inc3.57%
NKTR Nektar Therapeutics3.54%
ALXN Alexion Pharmaceuticals Inc3.54%
REGN Regeneron Pharmaceuticals3.51%
INCY Incyte Corp3.51%
BIIB Biogen3.49%
AGIO Agios Pharmaceuticals Inc3.44%